Target intelligence / Profile preview

Poly(ADP-ribose) polymerase 1, 2, and 3 (PARP1, PARP2, PARP3)

Target
PARP1, PARP2, PARP3
Molecular classification
Enzyme, Transferase, ADP-ribosyltransferase, DNA damage response protein
01

Overview

Poly(ADP-ribose) polymerases 1, 2, and 3 (PARP1, PARP2, PARP3) are closely related nuclear enzymes that play essential roles in cellular DNA damage detection and repair, especially in pathways such as base excision repair and non-homologous end joining. PARP1, the best-studied, detects DNA strand breaks and catalyzes the addition of ADP-ribose polymers to target proteins and itself (PARylation) using NAD(+) as a substrate, signaling and recruiting DNA repair machinery. PARP2 and PARP3 have distinct, though overlapping, roles in DNA repair and exhibit differences in activation and substrate specificity. Inhibition of these enzymes, especially PARP1 and PARP2, is therapeutically exploited in cancer, taking advantage of synthetic lethality in DNA repair-deficient cells, particularly those with BRCA mutations. Their activity also regulates cell death pathways, chromatin remodeling, and transcription, with dysregulation implicated in cancer, neurodegeneration, and inflammatory diseases.

Other names
PARP-1, ADPRT, ARTD1 (for PARP1)PARP-2, ADPRT2, ARTD2 (for PARP2)PARP-3, ADPRT3, ARTD3 (for PARP3)Poly ADP-ribose polymerase (collectively)DNA-dependent ADP-ribosyltransferases (collectively)
02

Mechanism of action

Inhibition of catalytic activity (compete with NAD(+) at the active site); "Trapping" of PARP enzymes on damaged DNA, blocking DNA repair; Induction of synthetic lethality in cells with deficient homologous recombination repair, e.g., BRCA-mutated cancers

03

Biological functions

DNA repair (base excision repair [BER], non-homologous end joining [NHEJ])DNA damage recognition and signalingRegulation of gene expression and chromatin structureCell death (necrosis and apoptosis)Epigenetic regulationCellular response to stress
04

Disease associations

CancerNeurodegenerative diseaseInflammationOther genetic disorders of DNA repair
05

Safety considerations

Myelosuppression (anemia, neutropenia, thrombocytopenia)Gastrointestinal toxicity (nausea, vomiting)FatigueRare risk of myelodysplastic syndrome/acute myeloid leukemiaPotential for resistance development in tumors
06

Interacting drugs

Olaparib

5 more in the full profile.

07

Biomarkers

BRCA1 and BRCA2 mutations (predict increased sensitivity to PARP inhibitors)Homologous recombination deficiency (HRD) status

Beyond the preview

Go deeper on Poly(ADP-ribose) polymerase 1, 2, and 3 (PARP1, PARP2, PARP3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Poly(ADP-ribose) polymerase 1, 2, and 3 (PARP1, PARP2, PARP3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call